TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Protego DF4 Post Approval Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Implanted within the last 30 days or candidate for implantation of a BIOTRONIK ICD or CRT-D DF4 compatible system along with the Protego DF4 lead~* Meets ICD or CRT-D system implant recommendations as defined in guidelines published by relevant professional societies~* Able to understand the nature of the registry and provide informed consent~* Available for follow-up visits on a regular basis at the investigational site for the expected 5 years of follow-up~* Age greater than or equal to 18 years~Exclusion Criteria:~* Enrolled in any investigational cardiac device trial~* Planned cardiac surgical procedures or interventional measures within the next 6 months~* Expected to receive heart transplantation or ventricular assist device within 1 year~* Life expectancy of less than 1 year~* Presence of another life-threatening, underlying illness separate from their cardiac disorder~* Patients reporting pregnancy at the time of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Azithromycin for Acute Exacerbations Requiring Hospitalization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Established diagnosis of COPD by medical doctor (based on clinical history OR pulmonary function test)~* Smoking history of at least 10 pack-years (10 pack-years are defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20 years, etc.)~* Current hospitalization for potential infectious AECOPD treated with standard therapy~* History of at least one exacerbation during the last year (prior to the current hospital admission) for which systemic steroids and/or antibiotics were taken~* ECG at admission~Exclusion Criteria:~* Mechanical or non-invasive ventilation at moment of randomization (D1)~* Long QT interval on ECG (QTc \> 450msec for males or \> 470msec for females)~* History of life-threatening arrhythmias~* Myocardial infarction (NSTEMI or STEMI) less than 6 weeks before start of study drug~* Unstable angina pectoris or acute myocardial infarction (NSTEMI or STEMI) at admission~* Drugs with high risk for long QT interval and torsade de pointes (amiodarone, flecainide, procainamide, sotalol, droperidol, haldol, citalopram, other macrolides)~* Documented uncorrected severe hypokalemia (K+ \< 3.0 mmol/L) or hypomagnesemia (Mg2+ \< 0.5 mmol/L)~* Chronic systemic steroids (\> 4 mg methylprednisolone /day for ≥ 2 months)~* Actual use of macrolides for at least 2 weeks~* Allergy to macrolides~* Active cancer treatment~* Life expectancy \< 3 months~* Pregnant or breast-feeding subjects. Woman of childbearing potential must have a pregnancy test performed and a negative result must be documented before start of treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azithromycin (Type: EXPERIMENTAL): N = 250~* From day 1 up to and including day 3: 500 mg azithromycin PO once a day~* From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days
- Placebo (Type: PLACEBO_COMPARATOR): N = 250~* From day 1 up to and including day 3: 500 mg placebo PO once a day~* From day 4 up to and including day 90: 250 mg placebo PO once every 2 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Plasma Injections Plus Exercise for Patellar Tendinopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18 and ≤ 50 years of age at Enrollment Visit~* Documentation of a clinical diagnosis of patellar tendinopathy, grade-IIIB Blazina stage, confirmed on ultrasound~* Previously tried an exercise program of at least six weeks duration~* Fluent in official language of study site~* Written informed consent obtained from subject~* Normal values on screening laboratory panels (CBC, PT, PTT, INR, serum creatine, ALT, ALP, AST, bilirubin, albumin)~Exclusion Criteria:~* For women of child-bearing potential, positive pregnancy test at enrollment visit~* Major surgery in the past three months~* Surgery on the symptomatic knee~* Bleeding disorder~* Systemic inflammatory disease~* Arthritis or degenerative knee condition~* Recent fluoroquinolone use~* Subjects who have any requirement for the use of systemic steroids or immunosuppressants~* Subjects who are known to be HIV positive~* Uncooperative patient, or patients who are incapable of following directions or who are predictably unwilling to return for follow-up examinations~* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Leukocyte-rich Platelet Rish Plasma + exercise (Type: EXPERIMENTAL): Leukocyte-rich PRP injection and a 12 week exercise program.
- Leukocyte-poor Platelet Rich Plasma + exercise (Type: EXPERIMENTAL): Leukocyte-poor PRP injection and a 12 week exercise program.
- Saline + exercise (Type: PLACEBO_COMPARATOR): Saline injection and a 12 week exercise program.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vaccines and Dietary Oats in the Treatment of Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* ulcerative colitis of at least 4 months duration~* disease activity index score (Walmsley) \>5 and \</=13~* patients taking no ulcerative colitis relevant medicine, or stable doses of aminosalicylates or maximum 10mg prednisolon daily the last 2 weeks before study entry. They must remain on the same dose throughout the study (6 months).~* stool examination negative for enteric pathogens, clostridium difficile toxin and parasites~Exclusion Criteria:~* ulcerative colitis disease activity index \>13~* symptoms of bowel obstruction~* other serious medical condition~* use of any of the study vaccines during the last two years~* use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first vaccine dose, or planned use during study period~* pregnant or planning to become pregnant~* breastfeeding~* chronic administration of prednisolone more than 10mg per day or steroids of equivalent dose the last 2 weeks before the first vaccine dose~* treatment with anti-tumor necrosis factor within 3 months prior to the first vaccine dose~* use of other immunosuppressants or immune modifying drugs within 30 days prior to the first vaccine dose

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 2 (Type: EXPERIMENTAL): Vaccination with Vivotif and Dukoral
- 3 (Type: EXPERIMENTAL): Dietary supplement with oats
- 4 (Type: PLACEBO_COMPARATOR): Placebo instead of vaccines No dietary supplement
- 1 (Type: EXPERIMENTAL): Vaccination with Vivotif and Dukoral + dietary supplement with oats.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Equivalence of Two Generic Butenafine Hydrochloride 1% Creams as Compared to Lotrimin Ultra Cream in Patients With Interdigital Tinea Pedis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or non-pregnant, non lactating females 18 years of age or older.~2. Signed informed consent form, which meets all criteria of current FDA regulations and the requirements of the India regulatory authorities.~3. If female and of child bearing potential, have a negative urine pregnancy test at the baseline visit,~4. A total score of at least six (6) for the following eight (8) clinical signs and symptoms of interdigital tinea pedis: fissuring, erythema, maceration, vesiculation, desquamation/scaling, exudation, pruritus, burning/stinging. In addition the most infected area must have a minimum score of at least 2 for erythema and a minimum score of at least 2 for either pruritus or desquamation/scaling~5. A confirmed clinical diagnosis of interdigital tinea pedis.~6. The presence of tinea pedis infection, confirmed by the observation of segmented fungal hyphae during a microscopic KOH wet mount examination (potassium hydroxide mount preparation).~7. Identification of an appropriate dermatophyte by culture sent to the central laboratory. The appropriate dermatophytes are Trichophyton rubrum, Trichophyton mentagrophytes or Epidermophyton floccosum.~Exclusion Criteria:~1. Use of any of the following within the indicated timeline:~   * Oral or injectable steroids within four weeks of the study start.~  * Any oral anti-fungals within 4 weeks of the study start.~  * Use of topical corticosteroids or any other topical antipruritics on the feet within 72 hours of the study start.~  * Any prescription or OTC topical antifungal on the feet within two weeks prior to study entry.~  * Use of any antihistamines within 72 hours of the study start.~2. Any known hypersensitivity to butenafine or other antifungal agents.~3. Evidence of any concurrent dermatophytic infection of toe nails (onychomycosis) or other dermatological condition of the foot that may interfere with the Investigators evaluation of tinea pedis.~4. Patients with recurrent tinea pedis (more than 3 infections in the past 12 months) who have been unresponsive to previous antifungal therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Butenafine Hydrochloride 1% A (Type: EXPERIMENTAL): 1
- Butenafine Hydrochloride 1% B (Type: EXPERIMENTAL): 2
- Butenafine Hydrochloride 1% (Type: ACTIVE_COMPARATOR): 3
- Vehicle A (Type: PLACEBO_COMPARATOR): 4
- Vehicle B (Type: PLACEBO_COMPARATOR): 5

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of the Visual Information Change in Functional Dystonia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Case~* Presenting a cervical dystonia that occurs only during handwriting tasks, diagnosed by a neurologist specialised in movement disorders~* Being treated or not by injection of Botulinum Neurotoxin (but last injection \> 3 months before the initial assessment)~Control~* No cervical dystonia~* Same sex, age (± 5 years), socio-professional level and hand laterality as the cases~Exclusion Criteria:~Case~* Cervical dystonia occuring in other circumstances than handwriting~* Neurological disease other than cervical dystonia (e.g. Parkinson's syndrome)~* Pain, trauma or pathology of the cervical spine of another cause than cervical dystonia and which have required medical or surgical treatment in the last 6 months preceding the initial assessment~Control~* Cervical disorders requiring medical or surgical treatment in the last 6 months prior to the tests~* Neurological disease affecting the cervical region or the writing hand~* Uncorrected visual disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 71 Years
- Healthy Volunteers: t

Study Arms:
- orthoptic treatment (Type: EXPERIMENTAL): Patients with cervical dystonia occuring only during handwriting.
- Controls (Type: NO_INTERVENTION): Patients without cervical dystonia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hyperinflation Assessment After Treatment by Lung Volume Reduction Coil

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Severe emphysema (recent CT-scan (\< 6 mois) )~* Age \> 35 ans~* Modified Medical Research Council Scale (mMRC) \> 2~* Forced expiratory volume in one second (FEV1) post-bronchodilatator \< 45%~* Residual volume \> 175%~* Total Pulmonary capacity \> 100%~Exclusion Criteria:~* Forced expiratory volume in one second (FEV1) variability \> 20% after bronchodilatator~* Carbon Monoxide Diffusing Capacity (TLCO) \< 20%~* Recurrent respiratory infection Infections with clinics symptoms~* Pulmonary arterial hypertension (PAH) with Pulmonary Arterial Systolic Pressure (PAPS) estimated with echography \> 50 mm Hg~* Impossibility to walk more that 140 meter (6 min test)~* Surgery history of volume reduction or pulmonary transplantation~* Broncho-dilatation with clinic symptoms

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patient with severe emphysema (Type: OTHER): Patients with severe emphysema, stable, symptomatic, not controlled despite of international recommendations treatments will have bronchoscopy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Robotic Surgery of the Ocular Surface

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patient \> 18 year-old suffering :~symptomatic pterygium~* chronic corneal ulceration resistant to medical treatment~* corneal opacity involving corneal stroma and corneal endothelium~* corneal thinning~* corneal perforation~Exclusion Criteria:~* History of eye surgery~* psychiatric disease~* mental deficiency~* pregnancy~* nursing mother

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Amniotic membrane transplantation (Type: OTHER): None
- Pterygium surgery (Type: OTHER): None
- Penetrating keratoplasty (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma Relapse

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Multiple Myeloma in first relapse.~* In Complete or very good partial remission~* Available Collected Autologous Peripheral Stem cells: 2.5x106 CD34+/Kg~Exclusion Criteria:~* Uncontrolled visceral disease: kidney, heart, lung, diabetes mellitus~* Previous Total body irradiation~* Any previous radiation dose to the spinal cord which could reach to 45gy equivalent, including the proposed TBMI~* Amyloidosis~* Brain localizations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Total BM irradiation dose (Type: EXPERIMENTAL): Total Bone Marrow Irradiation (TBMI) is delivered by the Tomotherapy HI-ART machine, in 2 fractions per day during 4 consecutive days from d -6 to d -3. The escalated dose levels are determined according to a 3x3 modified Fibonacci method and five dose levels will be explored. The doses per fraction are: 1gy, 1.25gy, 1.5gy, 1.75gy and 2gy, and consequently the cumulative TBMI doses are: 8gy, 10gy, 12gy, 14gy and 16gy.~For Every patients:~Drug : Melphalan is infused intravenously in 30 minutes on day -2 after IV anti-emetics.~Autologous Peripheral Stem Cell Rescue : are re-infused in the central line on day 0 after adequate premedication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cervical Pessary for Prevention of Spontaneous Preterm Birth in Singleton Pregnancies With Arrested Preterm Labor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Singleton gestations~* Diagnosis of arrested PTL~* 18-50 years of age~* TVU CL ≤25mm at the time of randomization~Exclusion Criteria:~* Multiple gestations~* Rupture of membranes at the time of randomization~* Known major fetal structural (i.e. defined as those that are lethal or require prenatal or postnatal surgery) or chromosomal abnormality~* Fetal death at the time of randomization~* Cerclage in situ at the time of randomization~* Pessary in situ at the time of randomization~* Vaginal bleeding at the time of randomization~* Women who are unconscious, severly ill, mentally handicapped, or under the age of 18 years~* Placenta previa and/or accreta~* Ballooning of membranes outside the cervix into the vaginal or TVU CL = 0mm at the time of randomization~* Painful and regular uterine contractions at the time of randomization

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Pessary (Type: EXPERIMENTAL): Silicon device applied on the cervix
- No Pessary (Type: ACTIVE_COMPARATOR): standard care, no pessary

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Methylphenidate on Non-motor Symptoms and Postural Control in Parkinson's Disease.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with stages 2-3 Parkinson's disease as defined by the Hoehn \&Yahr staging system (Hoehn \&Yahr, 1967).~* Age less than or equal to 75 years.~* Subjects who are willing and able to provide, in writing, informed consent.~* Subjects who are willing and able to be confined to the clinical research unit as required by the protocol and to complete all procedures required on an outpatient basis.~Exclusion Criteria:~* Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies and excluding seasonal allergies).~* Subjects with a history of substance abuse or dependence or a positive urine screen for drugs of abuse.~* A history of regular alcohol consumption exceeding 7 drinks/week for women or 14 drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of screening.~* Subjects with a documented allergy to methylphenidate or one of the product excipients.~* Subjects with any medical condition affecting drug absorption (e.g. gastrectomy).~* Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication.~* Use of a monoamine oxidase inhibitor or other interacting medication within the preceding 14 days or 5 half-lives (whichever is longer).~* History of sensitivity to heparin or heparin-induced thrombocytopenia.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Methylphenidate 10 (Type: EXPERIMENTAL): Methylphenidate 10mg three times daily for a total of 7 doses.
- Placebo 10 (Type: PLACEBO_COMPARATOR): Placebo capsule three times daily for a total of 7 doses.
- Methylpheindate 20 (Type: EXPERIMENTAL): Methylphenidate 20mg three times daily for a total of 7 doses.
- Placebo 20 (Type: PLACEBO_COMPARATOR): Placebo capsule three times daily for a total of 7 doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Study of the sensiTVT

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria~* Planned surgery for verified predominant stress urinary incontinence~* women between 18 and 80 years of age~* good German language skills~* informed consent~Exclusion criteria:~* Pregnant or lactating women~* Active surgical treatment for invasive malignant diseases within 3 months~* Contraindications for surgery or anesthesia~* Severe neurologic disease~* Concomitant prolapse surgery

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues